Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Clinical Trials (5)
Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B
PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5
Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Loss of Exclusivity
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8754065 | Aug 15, 2032 | SubstanceProduct | U-257 |
| 9296769 | Aug 15, 2032 | SubstanceProduct | U-257 |
| 8754065*PED | Feb 15, 2033 | — | |
| 9296769*PED | Feb 15, 2033 | — |